Dehydrocrenatidine Induces Liver Cancer Cell Apoptosis by Suppressing JNK-Mediated Signaling
Open Access
- 25 March 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (4) , 402
Abstract
Liver cancer is a leading cause of death worldwide. Despite advancement in therapeutic interventions, liver cancer is associated with poor prognosis because of highly lethal characteristics and high recurrence rate. In the present study, the anticancer potential of a plant-based alkaloid namely dehydrocrenatidine has been evaluated in human liver cancer cells. The study findings revealed that dehydrocrenatidine reduced cancer cell viability by arresting cell cycle at G2/M phase and activating mitochondria-mediated and death receptor-mediated apoptotic pathways. Specifically, dehydrocrenatidine significantly increased the expression of extrinsic pathway components (FAS, DR5, FADD, and TRADD) as well as intrinsic pathway components (Bax and Bim L/S) in liver cancer cells. In addition, dehydrocrenatidine significantly increased the cleavage and activation of PARP and caspases 3, 8, and 9. The analysis of upstream signaling pathways revealed that dehydrocrenatidine induced caspase-mediated apoptosis by suppressing the phosphorylation of JNK1/2. Taken together, the study identifies dehydrocrenatidine as a potent anticancer agent that can be use clinically to inhibit the proliferation of human liver cancer cells.Keywords
This publication has 24 references indexed in Scilit:
- Inverse Association of Fibrates and Liver Cancer: A Population‐Based Case‐Control Study in TaiwanThe Journal of Clinical Pharmacology, 2019
- Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An age‐period‐cohort analysisLiver International, 2018
- The Akt pathway in oncology therapy and beyond (Review)International Journal of Oncology, 2018
- Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical StudiesClinical Cancer Research, 2017
- Lead Phytochemicals for Anticancer Drug DevelopmentFrontiers in Plant Science, 2016
- Combination of anti-angiogenesis agents and transarterial embolization: Is it a promising approach for the treatment of liver cancer?2015
- Dehydrocrenatidine Is a Novel Janus Kinase InhibitorMolecular Pharmacology, 2015
- Alkaloids Isolated from Natural Herbs as the Anticancer AgentsEvidence-Based Complementary and Alternative Medicine, 2012
- Medicinal Plants: Historical and Cross-Cultural Usage PatternsAnnals of Epidemiology, 2005
- DNA fragmentation in apoptosisCell Research, 2000